Sanz Manrique N, Valcarce Pérez J, Broto Escapa P, Escribano Subías J, Casaldáliga Ferrer J, Moraga Llop F A, Sánchez de Toledo Codina J
Servicio de Oncología Pediátrica, Hospital Infantil Valle de Hebrón, Universidad Autónoma de Barcelona.
An Esp Pediatr. 1990 Jan;32(1):11-4.
We have studied 60 pediatric patients with different neoplastic diseases, treated with anthracyclines. We have followed them clinically and echocardiographically to detect the cardiotoxicity due to anthracyclines and the enhanced factors promptly. We have detected a more important incidence of cardiomyopathy in patients with non-Hodgkin's lymphoma, osteosarcoma and neuroblastoma despite cumulative doses under 550 mg/m2 of anthracyclines. The 2 first groups were treated with high doses of cyclophosphamide and methotrexate, and neuroblastomas with melphalan. The anthracyclines cardiotoxicity is evaluated around 5% in patients treated with doses under 550 mg/m2, and is increased in case of previous or simultaneous aggressive therapy. Continued echocardiography enables a premature detection of cardiotoxicity in these high risk patients.
我们研究了60例接受蒽环类药物治疗的患有不同肿瘤疾病的儿科患者。我们对他们进行了临床和超声心动图随访，以及时发现蒽环类药物所致的心脏毒性及相关增强因素。我们发现，尽管蒽环类药物累积剂量低于550mg/m²，但非霍奇金淋巴瘤、骨肉瘤和神经母细胞瘤患者的心肌病发生率更高。前两组患者接受了高剂量环磷酰胺和甲氨蝶呤治疗，神经母细胞瘤患者接受了美法仑治疗。接受低于550mg/m²剂量治疗的患者中，蒽环类药物心脏毒性的评估发生率约为5%，在既往或同时接受积极治疗的情况下会增加。持续的超声心动图检查能够在这些高危患者中早期发现心脏毒性。
